Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03260712
Title Pembrolizumab in Biliary Tract Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors European Organisation for Research and Treatment of Cancer - EORTC
Indications

gallbladder carcinoma

biliary tract cancer

Therapies

Cisplatin + Gemcitabine + Pembrolizumab

Age Groups: adult | senior
Covered Countries


No variant requirements are available.